Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144293 · ClinicalTrials.gov registry record · Phase 2
Improving Physical Ability and Cellular Senescence Elimination in HIV
A Phase 2 study of HIV and Frailty, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT07144293: Recruiting Phase 2 study of HIV and Frailty, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT07144293 is a Phase 2 study of HIV and Frailty that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 80 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07144293, a Phase 2 study of HIV and Frailty, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG Quercetin
- OTHER Placebo - Dasatinib
- OTHER Placebo - Quercetin
Study Locations (20)
California
- University of California, Los Angeles CARE Center CRS (Site ID: 601) - Los Angeles
- UCSD Antiviral Research Center CRS (Site ID: 701) - San Diego
- University of California, San Francisco HIV/AIDS CRS (Site ID: 801) - San Francisco
- Harbor University of California Los Angeles Center CRS (Site ID: 603) - Torrance
New York
- Weill Cornell Chelsea CRS (Site ID: 7804) - New York
- Columbia Physicians & Surgeons (P&S) CRS (Site ID: 30329) - New York
- Weill Cornell Uptown CRS (Site ID: 7803) - New York
- University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site ID: 31787) - Rochester
Massachusetts
- Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101) - Boston
- Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107) - Boston
North Carolina
- Chapel Hill CRS (Site ID: 3201) - Chapel Hill
- Greensboro CRS (Site ID: 3203) - Greensboro
Alabama
- Alabama CRS (Site ID: 31788) - Birmingham
Colorado
- University of Colorado Hospital CRS (Site ID: 6101) - Aurora
District of Columbia
- Whitman-Walker Institute, Inc. CRS (Site ID: 31791) - Washington D.C.
Georgia
- The Ponce de Leon Center CRS (Site ID: 5802) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2026-11-29 |
| Phase | Phase 2 |
What NCT07144293 shows while recruiting
NCT07144293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (82% lower).
The record links to 4 conditions, with HIV appearing as the primary indexed condition, and to 4 interventions - of which Dasatinib is the first listed.
NCT07144293 names 20 study sites across 12 states, led by California, New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07144293 about?
NCT07144293 is a clinical study titled "Improving Physical Ability and Cellular Senescence Elimination in HIV". This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living wit...
What is the current status of trial NCT07144293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-04. Estimated completion is 2026-11-29.
What conditions does trial NCT07144293 study?
This clinical trial studies the following conditions: HIV, Frailty, Aging Problems, Pre-frail.
What interventions are being tested in trial NCT07144293?
The interventions under investigation include: Dasatinib (DRUG), Quercetin (DRUG), Placebo - Dasatinib (OTHER), Placebo - Quercetin (OTHER).
Who is sponsoring clinical trial NCT07144293?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144293 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07144293's enrollment target sits among peer trials
80 175th of 303 higher than 124 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
-
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI